Hyperinterleukinemia, insulinresistance in hypertensive patients with prediabetes

Abstract

Interleukin-6 is pleiotropic cytokine with a key impact on immunoregulation and nonimmune events. Sudies have investigated the role of action/lack of action of Interleukin-6 in the pathogeneses obesity, insulin resistance, type 2 diabetes. Aim of the study: to evaluate interleukin-6 activity in hypertensive patients depend on prediabetes presence. Materials and methods: 73 hypertensive patients were examined. Common clinical investigations, were provided. Interleukin-6 plasma levels were detected using ELISA. Data is represented as Me (Q25-Q75). Median test were used, р <0,05. Results: Prediabetes was observed in 36,2% of hypertensive patients, in 71% insulinresistance in hypertensive patients with prediabetes vs 54 % insulinresistance in hypertensive patients were detected. Hypertensive patients with prediabetes (5,90 (5,20-7,10) %) characterized by significantly higher glycated haemoglobin levels as compared hypertensive patients (5,40 (4,70-6,97) %, р<0,05). Hypertensive patients were characterized by increased interleukin-6 activity (18,81 (13,14-26,69) pg/ml). In hypertensive patients with prediabetes decrease interleukin-6 activity (13,94 (11,00-16,94) pg/ml )were found. Conclusion: Hypertensive patients were characterized by increased interleukin-6 activity, in hypertensive patients with prediabetes decrease interleukin-6 activity were found, that can be explained by double effects of interleukin-6 family, representatives of which or can lead to insulinresistance development, or on the contrary can improve tissue insulinsensitivity. From other side, the possibility is not exclude that hypertension is a more strong incentive, which leads to hyperinterleukinemia in hypertensive patients.